BioLineRX
BLRX
26 hedge funds and large institutions have $34.9M invested in BioLineRX in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
378% more capital invested
Capital invested by funds: $7.3M → $34.9M (+$27.6M)
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
18% more funds holding
Funds holding: 22 → 26 (+4)
0.07% more ownership
Funds ownership: 0.02% → 0.1% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18.8M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.37M |
| 3 |
SM
Senvest Management
New York
|
+$3.23M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.72M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Menta Capital
San Francisco,
California
|
-$95K |
| 2 |
Jane Street
New York
|
-$15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
-$9.01K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
MC
27
Menta Capital
San Francisco,
California
| – | -$95K | -172 | Closed |
|
|
28
Jane Street
New York
| – | -$15K | -27 | Closed |
|
|
29
UBS Group
Zurich,
Switzerland
| – | -$14K | -25 | Closed |
|
BLRX Hedge Fund Activity: Q1 2017 in Review
26 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2017, worth a combined $34.9M — up 378% from $7.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLRX positions and 3 closed out — a net gain of 4 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $18.8M. The largest seller was Menta Capital, exiting entirely with an estimated $95K sold.
- 26 institutional investors held BioLineRX (BLRX) as of Q1 2017, up from 22 in Q4 2016.
- Funds reported $34.9M of BioLineRX stock for Q1 2017, up 378% quarter-over-quarter.
- 7 funds opened new BioLineRX positions in Q1 2017 and 3 closed out, a net change of +4 holders.
- The largest BioLineRX buyer in Q1 2017 was BVF Inc, an estimated $18.8M added.
- The largest BioLineRX seller in Q1 2017 was Menta Capital, an estimated $95K sold.
Based on aggregated 13F filings for Q1 2017.